Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-09-25Clinical Trial Update: LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV) [Phase 1, Phase 2]
Phase 1/2 LOC-R01 study evaluates lenalidomide and ibrutinib in combination with Rituximab-Methotrexate-Procarbazine-Vincristine (R-MPV) for…
-
CLINICAL_TRIALS research · 2025-09-25Clinical Trial Update: Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma [Phase 1]
This Phase 1 trial evaluates low-dose radiation as bridging therapy for relapsed or refractory B-cell non-Hodgkin lymphomas, including DLBCL…
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel [Phase 1]
Phase 1 clinical trial evaluating the safety of reinfusing axicabtagene ciloleucel (Axi-Cel-2) in patients with relapsed/refractory second-l…
-
CLINICAL_TRIALS research · 2025-09-22Clinical Trial Update: Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma [NA]
Clinical trial update on dose-reduced consolidation radiation therapy for patients with diffuse large B-cell lymphoma; the study is currentl…
-
CLINICAL_TRIALS research · 2025-09-19Clinical Trial Update: A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma [Phase 3]
A Phase III clinical trial is evaluating Purinostat Mesylate for injection in patients with recurrent or refractory diffuse large B-cell lym…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-09-19Clinical Trial Update: Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research [EARLY_Phase 1]
This early-phase (Phase 1) clinical trial investigates the safety and preliminary efficacy of Meta10-19 metabolically armed CD19 CAR-T cells…
-
CLINICAL_TRIALS trial_result · 2025-09-18Clinical Trial Update: Molecular Characterization and Outcomes of Aggressive B-Cell Lymphomas.
Completed clinical trial update reporting molecular characterization and outcomes in aggressive B-cell lymphomas, including Diffuse Large B-…
-
CLINICAL_TRIALS withdrawal · 2025-09-17Clinical Trial Update: A Phase 2 Trial of Glofitamab for Minimal Residual Disease in Patients With Large B-cell Lymphoma [Phase 2]
A Phase 2 trial evaluating glofitamab for minimal residual disease in patients with diffuse large B-cell lymphoma has been withdrawn.
-
CLINICAL_TRIALS research · 2025-09-17Clinical Trial Update: Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma [EARLY_Phase 1]
This clinical trial update reports an early-phase study of a novel Bispecific AbTCR (anti-CD19/CD22) T-cell therapy for relapsed or refracto…
-
CLINICAL_TRIALS research · 2025-09-16Clinical Trial Update: Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation [Phase 1]
Phase 1 trial evaluating Zanubrutinib in combination with Odronextamab for Richter transformation in transformed chronic lymphocytic leukemi…
-
CLINICAL_TRIALS trial_result · 2025-09-15Clinical Trial Update: Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab [Phase 1, Phase 2]
The Phase 1/2 trial evaluates Ociperlimab (BGB-A1217) in combination with tislelizumab or rituximab for relapsed or refractory diffuse large…
-
CLINICAL_TRIALS research · 2025-09-15Clinical Trial Update: Vaccine Responses in Patient With Multiple Myeloma and Non-Hodgkin Lymphoma After CAR-T Treatment
This clinical trial update describes a study assessing vaccine responses in patients who previously received CAR-T therapy for multiple myel…
-
CLINICAL_TRIALS research · 2025-09-11Clinical Trial Update: CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas [Phase 1]
This entry provides an update on an ongoing Phase 1 trial of CD19-targeted CAR T-cells (CD19.20.22) for relapsed/refractory B-cell lymphomas…
-
CLINICAL_TRIALS trial_result · 2025-09-10Clinical Trial Update: BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I) [Phase 1]
Phase I clinical trial update for BR101801 in adults with advanced hematologic malignancies; the study has completed.
-
CLINICAL_TRIALS research · 2025-09-09Clinical Trial Update: Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma [Phase 1]
A Phase 1 clinical trial update evaluating the combination of obinutuzumab, venetoclax, and lenalidomide in patients with relapsed or refrac…
-
CLINICAL_TRIALS research · 2025-09-08Clinical Trial Update: Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma [Phase 1, Phase 2]
This document outlines a Phase 1/2 clinical trial evaluating a combination of homoharringtonine, a BCL-2 inhibitor, rituximab, and prednison…
-
CLINICAL_TRIALS other · 2025-09-08Clinical Trial Update: A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001) [Phase 1, Phase 2]
This clinical trial update indicates that Nemtabrutinib (MK-1026) is being studied for relapsed or refractory hematologic malignancies in a …
-
CLINICAL_TRIALS trial_result · 2025-09-05Clinical Trial Update: Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating maplirpacept in combination with tafasitamab and lenalidomide for relapsed or refractory diffuse large B-cell lym…
-
CLINICAL_TRIALS research · 2025-09-05Clinical Trial Update: Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia [Phase 1]
A Phase 1 clinical trial update describes modified CD19/CD20 CAR-T cells for recurrent or refractory B-cell lymphoma or chronic lymphocytic …
-
CLINICAL_TRIALS trial_result · 2025-09-03Clinical Trial Update: A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma [Phase 2]
Phase 2 study evaluating two Rituximab-containing chemotherapy regimens with a PET-driven strategy in lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2025-08-28Clinical Trial Update: A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies [Phase 1]
The Phase 1 study evaluating AB308 in combination with AB122 in participants with advanced malignancies has been completed.
-
CLINICAL_TRIALS trial_result · 2025-08-24Clinical Trial Update: 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers [Phase 1]
This is a Phase 1 clinical trial update for a CAR T cell therapy (19(T2)28z1xx) in various B-cell cancers. The study is sponsored by Memoria…
-
CLINICAL_TRIALS research · 2025-08-24Clinical Trial Update: A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies [Phase 1]
Phase I study to establish safety and maximum tolerated dose of autologous BCMA-targeting CAR T-cells in relapsed/refractory diffuse large B…
-
CLINICAL_TRIALS other · 2025-08-22Clinical Trial Update: A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL. [Phase 2]
This entry describes a Phase 2 study of TRS005 in CD20-positive relapsed/refractory diffuse large B-cell lymphoma. The trial is currently no…
-
CLINICAL_TRIALS research · 2025-08-22Clinical Trial Update: A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL [Phase 1, Phase 2]
An early-phase Phase I/II trial evaluating TRS005 in combination with T-CHP (cyclophosphamide, doxorubicin, prednisone) for previously untre…